Cefa-DriThis page contains information on Cefa-Dri for veterinary use.
The information provided typically includes the following:
- Cefa-Dri Indications
- Warnings and cautions for Cefa-Dri
- Direction and dosage information for Cefa-Dri
Cefa-driThis treatment applies to the following species:
For Intramammary Infusion Into The Dry Cow
NADA 108-114, Approved by FDA
CEFA-DRI (cephapirin benzathine) for INTRAMAMMARY INFUSION into the DRY COW is a product which provides a wide range of bactericidal activity against gram-positive and gram-negative organisms. It is derived biosynthetically from 7-aminocephalosporanic acid.
Each 10 mL disposable syringe contains 300 mg of cephapirin activity in a stable peanut oil gel. This product was manufactured by a non-sterilizing process.
Store at controlled room temperature 15° to 30°C (59° to 86°F); avoid excessive heat.
In the non-lactating mammary gland, CEFA-DRI (cephapirin benzathine) provides bactericidal levels of the active antibiotic, cephapirin, for a prolonged period of time. This prolonged activity is due to the low solubility of the cephapirin benzathine and to the slow release gel base.
Cephapirin is bactericidal to susceptible organisms; it is known to be highly active against Streptococcus agalactiae and Staphylococcus aureus including strains resistant to penicillin.
To determine the susceptibility of bacteria to cephapirin in the laboratory, the class disc, Cephalothin Susceptibility Test Discs, 30 mcg, should be used.
For the treatment of mastitis in dairy cows during the dry period.
CEFA-DRI has been shown by extensive clinical studies to be efficacious in the treatment of mastitis in dry cows, when caused by Streptococcus agalactiae and Staphylococcus aureus, including penicillin-resistant strains.
Treatment of the dry cow with CEFA-DRI is indicated in any cow known to harbor any of these organisms in the udder at drying off.
Dosage And Directions For Use
CEFA-DRI (cephapirin benzathine) is for use in dry cows only. Infuse each quarter at the time of drying off with a single 10 mL syringe. Use no later than 30 days prior to calving.
Completely milk out all four quarters. The udder and teats should be thoroughly washed with warm water containing a suitable dairy antiseptic and dried, preferably using individual paper towels. Carefully scrub the teat end and orifice with 70% alcohol, using a separate swab for each teat. Allow to dry.
CEFA-DRI is packaged with the Opti-Sert® Protective Cap.
For Partial InsertionTwist off upper portion of the Opti-Sert Protective Cap to expose 3-4 mm of the syringe tip.
For Full InsertionRemove protective cap to expose the full length of the syringe tip.
Insert syringe tip into the teat canal and expel the entire contents of syringe into the quarter. Withdraw the syringe and gently massage the quarter to distribute the medication.
Do not infuse contents of the mastitis syringe into the teat canal if the Opti-Sert Protective Cap is broken or damaged.
CEFA-DRI should be administered with caution to subjects which have demonstrated some form of allergy, particularly to penicillin. Such reactions are rare; however, should they occur, consult your veterinarian.
1. For use in dry cows only.
2. Not to be used within 30 days of calving.
3. Milk from treated cows must not be used for food during the first 72 hours after calving.
4. Any animal infused with this product must not be slaughtered for food until 42 days after the latest infusion.
CEFA-DRI (cephapirin benzathine) for Intramammary Infusion into the Dry Cow. Cephapirin benzathine equivalent to 300 mg of cephapirin activity per syringe.
One 10 mL syringe
Carton containing 12 x 10 mL syringes
Opti-Sert® Protective Cap - U.S. Patent No. 4,850,970
Not for Human Use
Restricted Drug (California) - Use Only as Directed
© 2007 Fort Dodge Animal Health. All Rights Reserved.
Fort Dodge Animal Health, Fort Dodge, Iowa 50501 Usa
by G.C. Hanford Manufacturing Co., Syracuse, NY 13201
Rev. Oct. 2007
2621 NORTH BELT HIGHWAY, ST. JOSEPH, MO, 64506-2002
|Every effort has been made to ensure the accuracy of the Cefa-Dri information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|